Bioqube Ventures’ Post

Bioqube Ventures reposted this

View organization page for Bioqube Ventures, graphic

1,956 followers

Bioqube Ventures is pleased to welcome SynOx Therapeutics to its portfolio, co-leading a $75M Series B alongside existing investors Forbion and HealthCap. The proceeds will be used to generate registrational Phase 3 clinical and CMC data for emactuzumab, SynOx’s potentially best-in-class CSF-1R inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumours. #lifesciences #biopharma #oncology #investment https://lnkd.in/dHrb-uMN

  • No alternative text description for this image

Fantastic update! In exploring growth tactics, have you considered leveraging predictive analytics to refine your investment portfolio targeting? Implementing Machine Learning algorithms can significantly enhance your decision-making process, ensuring higher precision in future investments.

Like
Reply

Thank you to Jon Edwards, Krishna Polu, Roderick Verhelst PhD, MBA and the Bioqube Ventures team for your support on this round. Welcoming you to the company and the Board.

See more comments

To view or add a comment, sign in

Explore topics